A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
11/2002
11/28/2002	WO2002095067A2 INTERFERON α-14 POLYMORPHISM
11/28/2002	WO2002095043A1 Cellular signal-responsive gene transcriptional regulation system
11/28/2002	WO2002095042A1 Recombinant adenovirus vector producing tumor-suppressor e2 protein and the use thereof
11/28/2002	WO2002095041A1 Virus high effectively expressing the tumor interferon and specifically reproduction in tumor cells and the use thereof
11/28/2002	WO2002095038A2 Vectors for enhanced expression of vegf for disease treatment
11/28/2002	WO2002095034A2 A retinoic acid metabolizing cytochrome p450
11/28/2002	WO2002095030A2 Modulation of cd200 receptors
11/28/2002	WO2002095027A2 Immunostimulatory oligodeoxynucleic molecules
11/28/2002	WO2002095020A1 A gene and uses therefor
11/28/2002	WO2002095016A2 Champ - a cardiac helicase-like factor
11/28/2002	WO2002095011A2 Inactivation of genes of the mep pathway
11/28/2002	WO2002095007A2 Conjugates activated by cell surface proteases and therapeutic uses thereof
11/28/2002	WO2002095006A2 Muscle-specific expression vectors
11/28/2002	WO2002095001A2 Btf3: an inhibitor of apoptosis
11/28/2002	WO2002094997A2 Transcriptional regulation of target genes
11/28/2002	WO2002094996A2 Ccl1 polynucleotides and polypeptides and uses thereof
11/28/2002	WO2002094993A2 Kin28 polynucleotides and polypeptides and uses thereof
11/28/2002	WO2002094989A2 Retroviral vectors and methods of using same
11/28/2002	WO2002094983A2 Dna-antibody complexes to enhance gene transfer
11/28/2002	WO2002094875A1 HAb18G/CD147, IT'S AGONIST AND APPLICATION
11/28/2002	WO2002094872A1 Therapeutic uses of keratinocyte growth factor-2
11/28/2002	WO2002094871A1 Novel keratinocyte growth factor-2 analogue in hair follicle
11/28/2002	WO2002094870A2 Proteins and nucleic acids encoding same
11/28/2002	WO2002094868A2 Staphylococcus aureus proteins and nucleic acids
11/28/2002	WO2002094864A2 Human cdnas and proteins and uses thereof
11/28/2002	WO2002094863A2 INTERFERON-α INDUCED GENE
11/28/2002	WO2002094862A2 Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
11/28/2002	WO2002094852A2 Taci-immunoglobulin fusion proteins
11/28/2002	WO2002094845A2 Method for stabilising of nucleic acids
11/28/2002	WO2002094378A2 Increased functional activity and/or expression of abc transporters protects against the loss of dopamine neurons associated with parkinson's disease
11/28/2002	WO2002094313A2 Vaccine composition
11/28/2002	WO2002094310A1 Anti-angiogenic and immunotherapeutic compositions for cancer treatment
11/28/2002	WO2002094308A1 Improved neuronal gene transfer
11/28/2002	WO2002094307A1 Yin yang-1
11/28/2002	WO2002094306A1 Remedies for nervous tumor
11/28/2002	WO2002094194A2 Compositions and methods for inhibiting metastasis
11/28/2002	WO2002094177A2 Novel nucleic acids and their therapeutic use in ophthalmology
11/28/2002	WO2002080648A3 Mucosal boosting following parenteral priming
11/28/2002	WO2002077154A3 Gene delivery device and gene delivery method
11/28/2002	WO2002070563A3 Nuclear hormone receptor ligand binding domain
11/28/2002	WO2002066636A3 T cell receptor variants expressed in mesenchymal cells and uses thereof
11/28/2002	WO2002040538A3 Regulation of human nmda receptor
11/28/2002	WO2002038782A3 Viral expression system
11/28/2002	WO2002036733A3 Cd36 as a heat shock protein receptor and uses thereof
11/28/2002	WO2002035235A3 Net as regulator of angiogenic expression
11/28/2002	WO2002034920A3 Regulation of human ceruloplasmin-like protein
11/28/2002	WO2002024924A3 Protein phosphatases
11/28/2002	WO2002022177A3 High efficiency cardiac gene transfer
11/28/2002	WO2002008255A3 Cell cycle proteins and mitosis-associated molecules
11/28/2002	WO2001098360A3 Gp354 nucleic acids and polypeptides
11/28/2002	WO2001096393A9 Nucleotide and amino acid sequences of oocyte factors for altering ovarian follicular growth in vivo or in vitro
11/28/2002	WO2001095919A3 A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
11/28/2002	WO2001090345A3 Methods and compositions for enhancing the delivery of a nucleic acid to a cell
11/28/2002	WO2001068911A3 Diagnosis of diseases associated with the cell cycle
11/28/2002	WO2001018021A9 B7-like polynucleotides, polypeptides, and antibodies
11/28/2002	WO2000050070A9 Preparation for the treatment of pigmentation disorders
11/28/2002	US20020178458 Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd534 as a target
11/28/2002	US20020178135 Image searching system and image searching method, and a recording medium storing an image searching program
11/28/2002	US20020177575 Identification of farnesyl-protein transferase as a target for systemic lupus erythematosus therapies
11/28/2002	US20020177574 Endometrial gene therapy
11/28/2002	US20020177572 Viral infection of cells
11/28/2002	US20020177571 Retroviral vector particle comprising a modified viral surface protein for targeting the vector (especially to the Von Willebrand factor) and a cytokine gene.
11/28/2002	US20020177568 Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B
11/28/2002	US20020177553 Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/28/2002	US20020177552 Colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions; alternatively, antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a
11/28/2002	US20020177550 Administering to the subject a therapeutically effective amount of a form of soluble Receptor for Advanced Glycation Endproducts (RAGE).
11/28/2002	US20020177544 Adenoviral transfer vector for the gene transport of a dna sequence
11/28/2002	US20020177222 Replication competent AAV helper functions
11/28/2002	US20020177215 Methods for producing purified adenoviral vectors
11/28/2002	US20020177213 Tissue plasminogen activator-like protease
11/28/2002	US20020177191 Compound for use inthe diagnosis and treatment of cancer, viral, asthmatic, autoimmune, organ transplant rejection and infections
11/28/2002	US20020177150 Nucleoside composition for use as tool in human therapeutics and diagnositcs
11/28/2002	US20020177145 Detection and classification of nervous system progenitor cells; obtain tissue, monitor expression of daedalos protein in sample, compare to control, ampified daedalos expression indicates presence of nervous system progenitor cells
11/28/2002	US20020177125 Polypeptide for use in the treatment of viral disease
11/28/2002	US20020176852 Mitogenic oxygenase regulators
11/28/2002	US20020176851 Aministering to mammal an effective amount of therapeutic cells, expressing a membrane-bound, proteinaceous chimeric receptor, capable recognizing and binding target cell or infective agent; antitumor therapy
11/28/2002	US20020176848 Antimicrobial mediated bacterial DNA delivery
11/28/2002	US20020176847 Administering to a mammal viral vectors for treating and preventing atherosclerosis, osteoporosis, cardiovascular disease, Alzheimer's disease, diabetes mellitus, infectious diseases, cancer, and inherited disorders
11/28/2002	US20020176818 Radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid
11/28/2002	DE10212572A1 Bone formation controlling composition, especially for treatment of osteoporosis, containing ANK-pyrophosphate channel modulator, e.g. human ANK gene variant or probenecid
11/28/2002	DE10123133A1 New proteins binding specifically to the ED-b fibronectin domain, are cell adhesion and proliferation mediators useful e.g. in screening tests
11/28/2002	DE10123041A1 New single-chain human antibody fragment, useful for treating or diagnosing hepatitis C virus infection, has affinity for an essential viral protein
11/28/2002	CA2448668A1 Modulation of cd200 receptors
11/28/2002	CA2448253A1 Human cdnas and proteins and uses thereof
11/28/2002	CA2448132A1 Vectors for enhanced expression of vegf for disease treatment
11/28/2002	CA2448120A1 Muscle-specific expression vectors
11/28/2002	CA2448031A1 Method for stabilising of nucleic acids
11/28/2002	CA2448018A1 Compositions and methods for inhibiting metastasis
11/28/2002	CA2447958A1 Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
11/28/2002	CA2447942A1 A gene and uses therefor
11/28/2002	CA2447793A1 Immunostimulatory oligodeoxynucleic molecules
11/28/2002	CA2447616A1 Vaccine composition
11/28/2002	CA2447023A1 Conjugates activated by cell surface proteases and therapeutic uses thereof
11/28/2002	CA2446510A1 Therapeutic agent for tumor of neural origin
11/28/2002	CA2444955A1 Inactivation of genes of the mep pathway
11/28/2002	CA2440368A1 Staphylococcus aureus proteins and nucleic acids
11/28/2002	CA2438597A1 Champ - a cardiac helicase-like factor
11/27/2002	EP1260587A2 Tyrosyl tRNA synthetase
11/27/2002	EP1260586A2 Method and reagent for inhibiting the expression of disease related genes
11/27/2002	EP1260520A2 Chromosome 13-linked breast cancer susceptibility gene

1 ... 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 ... 870